A ONE-WAY DRUG DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF EFAVIRENZ ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF BMS-790052 IN HEALTHY SUBJECTS

A ONE-WAY DRUG DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF EFAVIRENZ ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF BMS-790052 IN HEALTHY SUBJECTS - BMS-790052/efavirenz drug-drug interaction study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON36747

Enrollment

Registered

2011-01-20

Start date

2011-02-17

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C Hepatitis C viral liver inflammation

Interventions

Active substance: BMS-790052, Efavirenz

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age: 18-49 years, inclusive BMI: 18.0 - 32.0 kg/m2, inclusive Females should be post menopausal or surgically sterile

Exclusion criteria

Exclusion criteria: Suffering from: hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 90 days from the start of the study or in case of donating more than 1 liter of blood (men) or more than 1.5 liter of blood (women) in the 10 months prior the start of this study.

Design outcomes

Primary

Measure	Time frame
- Pharmacokinetics - Safety	—

Secondary

Measure	Time frame
N.a.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)